CogstateFRA:C4B +1.82%69 OCF Yield % is 2.89 as of Jun. 24, 2026, which is 17% above its 10-year median of 2.46. GuruFocus rates FRA:C4B with a GF Score™ of 69/100 and a GF Value™ of €1.35 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 685 Healthcare Providers & Services companies, Cogstate ranks worse than 60.58% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Cogstate's OCF Yield % or its related term are showing as below:
FRA:C4B'
s OCF Yield % Range Over the Past 10 Years
Min: -3.48 Med: 2.46 Max: 8.69
Current: 2.89
During the past 13 years, the highest OCF Yield % of Cogstate was 8.69%. The lowest was -3.48%. And the median was 2.46%.
FRA:C4B's OCF Yield % is ranked worse than 60.58% of 685
companies
in the Healthcare Providers & Services industry
Industry Median: 5.56
vs FRA:C4B: 2.89
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cogstate OCF Yield % Related Terms
Cogstate OCF Yield % Historical Data
* Premium members only.
The historical data trend for Cogstate's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:C4B vs VEEV, BTSG, TEM: OCF Yield % Comparison
For the Health Information Services subindustry, Cogstate's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogstate OCF Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Cogstate's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogstate (FRA:C4B) has a OCF Yield % of 2.89 as of Jun. 24, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cogstate and its competitors. This is 17% above median its historical median of 2.46. According to the industry distribution chart, Cogstate ranks #415 out of 685 companies in the Healthcare Providers & Services industry, placing it in the top 60.6%.
Is Cogstate's OCF Yield % too high?
Cogstate's current OCF Yield % of 2.89 is 17% above median its 10-year median of 2.46. The Healthcare Providers & Services industry median OCF Yield % is 5.56. Cogstate's value of 2.89 is 48% below this industry median. Based on the distribution chart, Cogstate ranks #415 out of 685 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cogstate has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's OCF Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #415 out of 685 companies for OCF Yield %. This places Cogstate in the lower half of its industry. The industry median OCF Yield % is 5.56. Cogstate's value of 2.89 is 48% below this benchmark. While the company's 10-year median is 2.46 vs. the industry median of 5.56, Cogstate has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Healthcare Providers & Services company?
The median OCF Yield % among Healthcare Providers & Services companies is 5.56, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current OCF Yield % of 2.89 is 48% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cogstate and its competitors. For the Healthcare Providers & Services industry, the median OCF Yield % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current OCF Yield % is 2.89, which is 17% above median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (FRA:C4B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.35, compared to a current price of €1.68 — trading 24.4% above its estimated fair value. The current OCF Yield % is 2.89, which is 17% above median its 10-year median of 2.46 and 48% below the Healthcare Providers & Services industry median of 5.56. Cogstate's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Cogstate (FRA:C4B), the current OCF Yield % is 2.89 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (FRA:C4B) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of €1.68 is trading 24.4% above its estimated GF Value™ of €1.35.
GuruFocus considers Cogstate to be Modestly Overvalued.
Key valuation signals for FRA:C4B:
OCF Yield %: 2.89 (17% above median its 10-year median of 2.46)
GF Value™: €1.35 vs. price of €1.68 (24.4% above fair value)
Industry Position: 48% below the Healthcare Providers & Services median (#415 of 685)
No single metric tells the full story. See the FRA:C4B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
69GF Score
Get the complete analysis for FRA:C4B
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C4B has been successfully added to your 
